p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft Gynäkologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group

Woelber, Linn; Eulenburg, Christine zu; Oliveira‐Ferrer, Leticia; Gregorio, Nikolaus de; Klapdor, R; Kalder, Matthias; Braicu, Elena Ioana; Fuerst, Sophie; Klar, Maximilian; Strauß, Hans‐Georg; Beckmann, Matthias W.; Meier, W.; Ignatov, Atanas; Mustea, Alexander; Jueckstock, J; Schmidt, Georg; Bauerschlag, Dirk; Hellriegel, Martin; Canzler, Ulrich; Petry, Karl Ulrich; Kommoss, Stefan; Hantschmann, Peer; Heubner, Martin; Mahner, Sven; Burandt, Eike

doi:10.1016/j.ajog.2020.12.1220

Cited by 25 publications

(30 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Irrespective of clinicopathological differences ( Table 1 ), the HE-morphology does not allow for reliable differentiation between HPV-associated and HPV-independent (p53-associated) squamous cell carcinoma 2 , 4 , as it has an error rate of 20 – 30% 8 , 9 . The third pathogenetic concept postulated by Nooij et al 10 (see below; Table 1 ; 5 , 11 ) is not included in the new WHO classification as the current data are still insufficient.…”

Section: Vulvar Tumorsmentioning

confidence: 99%

“… Clinicopathological characteristics of the 2020 WHO classification of squamous cell carcinoma of the female genitals 1 , 5 , 6 , 8 , 9 , 11 , 12 , 13 , 14 , 17 , 18 , 20 , 24 , 27 , 44 . …”

Section: Vulvar Tumorsmentioning

confidence: 99%

“…In these patient groups with very different therapeutic approaches, it has now been acknowledged that p16-positive carcinomas have a better prognosis compared with those that are p53-positive 5 , 6 , 11 , 19 . The study by McAlpine et al 20 points out that patients with p53-positive tumors benefit from a more radical surgical approach.…”

Section: Vulvar Tumorsmentioning

confidence: 99%

“…Initial molecular studies show that vulvar carcinoma with a p53 mutation and an additional PIK3CA comutation have a particularly unfavorable prognosis 7 . There also clearly exists a third pathogenetic group of p16 − /p53 − tumors, which ranks prognostically between the p16-positive and the p53-aberrant vulvar carcinoma 5 , 11 ( Table 1 ). Whether or not the prognostically favorable low-grade squamous cell carcinoma with verrucous morphology represents one morphological end of the p16 − /p53 − tumor spectrum 7 is still unclear.…”

Section: Vulvar Tumorsmentioning

confidence: 99%

See 3 more Smart Citations

2020 WHO Classification of Female Genital Tumors

Höhn

Brambs

Hiller

et al. 2021

Geburtshilfe Frauenheilkd

140

View full text Add to dashboard Cite

The 2020 WHO classification is focused on the distinction between HPV-associated and HPV-independent squamous cell carcinoma of the lower female genital organs. Differentiating according to HPV association does not replace the process of grading; however, the WHO classification does not recommend any specific grading system. VIN are also differentiated according to whether they are HPV(p16)-associated. HPV-independent adenocarcinoma (AC) of the cervix uteri has an unfavorable prognosis. Immunohistochemical p16 expression is considered to be a surrogate marker for HPV association. HPV-associated AC of the cervix uteri is determined using the prognostically relevant Silva pattern.

show abstract

Section: Vulvar Tumorsmentioning

confidence: 99%

Section: Vulvar Tumorsmentioning

confidence: 99%

Section: Vulvar Tumorsmentioning

confidence: 99%

Section: Vulvar Tumorsmentioning

confidence: 99%

See 2 more Smart Citations

2020 WHO Classification of Female Genital Tumors

Höhn

Brambs

Hiller

et al. 2021

Geburtshilfe Frauenheilkd

140

View full text Add to dashboard Cite

show abstract

“…High-risk HPV infection is related to vulvar intraepithelial neoplasia, basaloid, and warty carcinomas. In a retrospective study, p16 immunohistochemistry was positive in 166 of 550 tumors (30.2%) and p53 staining in 187 of 597 tumors (31.3%) [106]. Dysregulated cell cycle markers including increased expression of cyclin D1, and cyclin A has also been shown in vulvar carcinomas.…”

Section: Mirnas In Vulvar Tumorsmentioning

confidence: 99%

Could MicroRNAs Be Useful Tools to Improve the Diagnosis and Treatment of Rare Gynecological Cancers? A Brief Overview

Fiore

Suleiman

Pentimalli

et al. 2021

IJMS

View full text Add to dashboard Cite

Gynecological cancers pose an important public health issue, with a high incidence among women of all ages. Gynecological cancers such as malignant germ-cell tumors, sex-cord-stromal tumors, uterine sarcomas and carcinosarcomas, gestational trophoblastic neoplasia, vulvar carcinoma and melanoma of the female genital tract, are defined as rare with an annual incidence of <6 per 100,000 women. Rare gynecological cancers (RGCs) are associated with poor prognosis, and given the low incidence of each entity, there is the risk of delayed diagnosis due to clinical inexperience and limited therapeutic options. There has been a growing interest in the field of microRNAs (miRNAs), a class of small non-coding RNAs of ∼22 nucleotides in length, because of their potential to regulate diverse biological processes. miRNAs usually induce mRNA degradation and translational repression by interacting with the 3′ untranslated region (3′-UTR) of target mRNAs, as well as other regions and gene promoters, as well as activating translation or regulating transcription under certain conditions. Recent research has revealed the enormous promise of miRNAs for improving the diagnosis, therapy and prognosis of all major gynecological cancers. However, to date, only a few studies have been performed on RGCs. In this review, we summarize the data currently available regarding RGCs.

show abstract

Implementation of quality indicators for vulvar cancer in gynaecological cancer centres certified by the German Cancer Society (DKG)

Stuebs,

Beckmann,

Dannecker

et al. 2024

J Cancer Res Clin Oncol

Self Cite

View full text Add to dashboard Cite

Purpose In 2018, the first guideline-based quality indicators (QI) for vulvar cancer were implemented in the data-sheets of certified gynaecological cancer centres. The certification process includes guideline-based QIs as a fundamental component. These indicators are specifically designed to evaluate the level of care provided within the centres. This article aims to give an overview of the developing process of guideline based-QIs for women with vulvar cancer and presents the QIs results from the certified gynaecological cancer centres. Methods The QIs were derived in a standardized multiple step process during the update of the 2015 S2k guideline “Diagnosis, Therapy, and Follow-Up Care of Vulvar Cancer and its Precursors” (registry-number: no. 015/059) and are based on strong recommendations. Results In total, there are eight guideline-based QIs for vulvar cancer. Four QIs are part of the certification process. In the treatment year 2021, 2.466 cases of vulvar cancer were treated in 177 centres. The target values in the centres for pathology reports on tumour resection and lymphadenectomy as well as sentinel lymph nodes have increased since the beginning of the certification process and have been above 90% over the past three treatment years (2019–2021). Discussion QIs based on strong guideline recommendations, play a crucial role in measuring and allowing to quantify essential aspects of patient care. By utilizing QIs, centres are able to identify areas for process optimization and draw informed conclusions. Over the years the quality of treatment of vulvar cancer patients measured by the QIs was improved. The certification system is continuously reviewed to enhance patient care even further by using the outcomes from QIs revaluation.

show abstract

p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft Gynäkologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group

Cited by 25 publications

References 42 publications

2020 WHO Classification of Female Genital Tumors

2020 WHO Classification of Female Genital Tumors

Could MicroRNAs Be Useful Tools to Improve the Diagnosis and Treatment of Rare Gynecological Cancers? A Brief Overview

Implementation of quality indicators for vulvar cancer in gynaecological cancer centres certified by the German Cancer Society (DKG)

Contact Info

Product

Resources

About